

2025 Avera Research Grand Rounds

2025 Avera Research Grand Rounds - 5/16/2025

05/16/2025 at 03:00 PM to 05/16/2025 at 04:00 PM

Live Activity

Purpose:

Avera Research Grand Rounds provides an opportunity for researchers across Avera to present their work to a broad audience of like-minded individuals with the intent of fostering cooperative interactions and improved understanding of ongoing research among investigators within Avera.

Objectives:

- 1 Review pertinent background information regarding venous thromboembolism (VTE) in multiple myeloma as well as the current recommendations for risk stratification and primary prophylaxis based on the National Comprehensive Cancer Network guidelines - Krebs
- 2 Summarize results from a retrospective cohort study on the incidence of VTE in patients with multiple myeloma on immunomodulatory drugs based on VTE prophylaxis strategy and VTE risk within a single health system - Krebs
- 3 Discuss potential standardization approaches for VTE risk assessment and primary VTE prophylaxis - Krebs
- 4 Review the current literature on trilaciclib and its efficacy in reducing cytopenic events in small cell lung cancer patients - Allbee
- 5 Assess the need to include trilaciclib in a patient's chemotherapy regimen for small cell lung cancer based on cytopenic events at Avera Cancer Center's primarily rural cancer centers - Allbee
- 6 Identify the benefit of in terms of efficacy and cost for trilaciclib on reducing cytopenic events and need for other interventions to correct the side effects of chemotherapy - Allbee

Target Audience:

Physician, Nurse - RN, Pharmacist

For successful completion:

- Attend education
- Complete evaluation

Accreditation & Credit Designation:

Accreditation



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, Avera is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Continuing Education Credit Designation(s)



IPCE CREDIT™

IPCE (Team-based): This activity was planned by and for the healthcare team, and learners will receive 1.00 IPCE credit(s) for learning and change.

REMINDER

Attendance can be texted up to 24 hours after the activity



Medicine CME: Avera designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME of the American Board of Surgery's Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.

Nurse CE: Avera designates this activity for a maximum of 1.00 ANCC contact hour(s). Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacy CE: Avera designates this activity for 1.00 ACPE contact hour(s). Pharmacists and pharmacy technicians should claim only the credit commensurate with the extent of their participation in the activity. Credit will be uploaded to the NABP CPE Monitor[®] within 30 days after the activity completion. Per ACPE rules, Avera does not have access nor the ability to upload credits requested after the evaluation closes. It is the responsibility of the pharmacist or pharmacy technician to provide the correct information (NABP ID and DOB (MMDD)) to receive credit.

Additional Information:

- Feedback person for this educational activity is: hannah.koble@avera.org

Disclosure Policy:

Due to the regulations required for CE credits, all conflicts of interest that persons in a position to control or influence the education must be fully disclosed to participants. In observance of this requirement, we are providing the following disclosure information: all relevant financial relationships disclosed below have been mitigated.

| Name of individual | Individual's role in activity | Nature of Relationship(s) / Name of Ineligible Company(s) |
|--------------------------------------|--|--|
| Benjamin Solomon, MD, Physician | Committee Planning Member | Nothing to disclose - 04/28/2025 |
| David Starks, MD | Committee Planning Member | Nothing to disclose - 08/20/2024 |
| Casey B Williams, PharmD, Pharmacist | Content Expert - Committee Member, Faculty, Lead Planner | Paid consultant-Faeth (Relationship has ended) - 06/12/2024 |
| Hannah Koble | Proxy | Nothing to disclose - 08/27/2024 |
| Tara Miller, BSN, Nurse | Lead Planner | Nothing to disclose - 06/18/2024 |
| Tobias Meissner, PhD, Researcher | Committee Planning Member | Nothing to disclose - 09/09/2024 |
| Amy Elliott, Ph D, Researcher | Committee Planning Member | Nothing to disclose - 12/03/2024 |
| Jyoti Angal, Ph D, Researcher | Committee Planning Member | Nothing to disclose - 12/02/2024 |
| William Spanos, MD | Committee Planning Member, Faculty | Grant or research support-National Institutes of Health - 04/11/2025 |
| Nicole Krebs, PharmD, Pharmacist | Faculty | Nothing to disclose - 11/19/2024 |
| Kyle Allbee, PharmD, Pharmacist | Faculty | Nothing to disclose - 02/14/2025 |

REMINDER

Attendance can be texted up to 24 hours after the activity